Zimbabwe has turned down a significant US healthcare agreement worth 367 million US dollars (272 million pounds) spanning five years over Washington's request for sensitive information.
This move came to light after a official document from December was leaked, revealing that Head of State Emmerson Mnangagwa believed the deal was "unbalanced".
A government spokesperson has since explained that the US was requesting biological samples for scientific study and commercial purposes while was unwilling to share the benefits from future vaccines.
"We must now begin the challenging and unfortunate task of ending our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had provided over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for continued talks to find a deal suitable to all parties so the country's vital HIV treatment initiative can be sustained.
Wider Background
This development comes after a similar case in neighbouring Kenya, where a court halted a similar health funding agreement following legal challenges were filed about the security of citizens' medical information.
After resuming the presidency last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
The agency had overseen aid for the American government, but Trump claimed its expenditure was "inefficient" and his government was seeking government-to-government agreements to boost openness and responsibility.
Based on statements, 16 African countries have to date signed these new health pacts, constituting over $18.3bn in new funding.
Details of the Rejected Deal
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership might have yielded significant benefits for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment via American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to provide its biological resources and data indefinitely, with no equivalent promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that provided information," he stated.
"Put simply, our nation would supply the basic resources for medical research without any assurance that the final treatments would be available to our people if a new disease outbreak emerge."
Sovereignty and International Frameworks
He also said that the American exit from the global health body and its pursuit of one-on-one deals were disrupting frameworks already set up via the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework designed to manage future pandemics.
"This framework is designed to guarantee that when a country provides its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the funds to develop them."
The government's concerns regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to ongoing dialogue with our US partners on how subsequent co-operation might be structured in a way that respects the independence and dignity of both nations."
Health Experts Response
Medical experts said it understood the government's concerns, but urged that negotiations need to persist considering a large portion of the nation's Aids initiatives relied on international support.
"In cases where specific concerns exist, including those involving information security or implementation frameworks, these can frequently be resolved through technical clarification and negotiated safeguards," it commented.
The situation underscores the ongoing debate between receiving much-needed international aid and protecting local interests in an increasingly interconnected world.